SCHEMBL23780338

SCHEMBL23780338

O=C(O)c1ccnn1-c1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
GAA P10253 2/20 0.46
APP P05067 1/20 0.46
HCAR3 P49019 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
NAMPT P43490 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HSD11B1 P28845 1/20 0.42
GRM1 Q13255 2/20 0.41
CYP2A6 P11509 2/20 0.41
HTT P42858 1/20 0.40
NFE2L2 Q16236 1/20 0.40
MARS1 P56192 1/20 0.40
CYP11B2 P19099 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
KDM4C Q9H3R0 1/20 0.39
CYP3A4 P08684 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30235475 0.85 F7 (0.47) ALDH1A1NAMPTSMN1; SMN2HSD11B1GRM1
SCHEMBL856957 0.84 POLB (0.52) ALDH1A1GAASMN1; SMN2HTTNFE2L2
SCHEMBL23780337 0.83 HCAR2 (0.41) ALDH1A1GAAAPPHCAR3HCAR2
Hydrochloric Acid SCHEMBL11893514 0.82 POLB (0.50) ALDH1A1GAASMN1; SMN2HTTNFE2L2
SCHEMBL23780341 0.79 NAPRT (0.43) ALDH1A1GAASMN1; SMN2KDM4CNAPRT
SCHEMBL27871752 0.78 AR (0.33) ALDH1A1HCAR2NAMPTSMN1; SMN2HSD11B1
SCHEMBL1759058 0.75 ALDH1A1 (0.52) ALDH1A1GAAGRM1MARS1
SCHEMBL16652812 0.75 ALDH1A1 (0.49) ALDH1A1GAAAPPHCAR3HCAR2
SCHEMBL29478778 0.75 ALDH1A1 (0.52) ALDH1A1GAAGRM1MARS1
SCHEMBL27758229 0.74 NR3C2 (0.48) KDM4CIDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210278408-A1 METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS BANTAM PHARMACEUTICAL LLC (US) 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210278408-A1 METHODS OF TREATMENT OF CANCER WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS AND DIAGNOSIS OF CANCERS SUSCEPTIBLE TO TREATMENT WITH SUBSTITUTED PYRROLE AND PYRAZOLE COMPOUNDS TP53, MKI67, VHL ALDH1A1 335/4885GAA 4042/4885APP 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.